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Background: Tardive dyskinesia (TD) is a common side effect of antipsychotic
treatment. This movement disorder consists of orofacial and limb-truncal components.
The present study is aimed at investigating the role of serotonin receptors (HTR) in
modulating tardive dyskinesia by genotyping patients with schizophrenia.
Methods: A set of 29 SNPs of genes of serotonin receptors HTR1A, HTR1B, HTR2A,
HTR2C, HTR3A, HTR3B, and HTR6 was studied in a population of 449 Caucasians
(226 females and 223 males) with verified clinical diagnosis of schizophrenia (according
to ICD-10: F20). Five SNPs were excluded because of low minor allele frequency or
for not passing the Hardy-Weinberg equilibrium test. Affinity of antipsychotics to 5-HT2
receptors was defined according to previous publications. Genotyping was carried out
with SEQUENOM Mass Array Analyzer 4.
Results: Statistically significant associations of rs1928040 of HTR2A gene in groups
of patients with orofacial type of TD and total diagnosis of TD was found for alleles,
and a statistical trend for genotypes. Moreover, statistically significant associations were
discovered in the female group for rs1801412 of HTR2C for alleles and genotypes.
Excluding patients who used HTR2A, respectively, HTR2C antagonists changed little
to the associations of HTR2A polymorphisms, but caused a major change of the
magnitude of the association of HTR2C variants. Due to the low patient numbers, these
sub-analyses did not have significant results.
Conclusion: We found significant associations in rs1928040 of HTR2A and for
rs1801412 of X-bound HTR2C in female patients. The associations were particularly
related to the orofacial type of TD. Excluding patients using relevant antagonists
particularly affected rs1801412, but not rs1928040-related associations. This suggest
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that rs1801412 is directly or indirectly linked to the functioning of HTR2C. Further
study of variants of the HTR2C gene in a larger group of male patients who were
not using HTR2C antagonists is necessary in order to verify a possible functional role
of this receptor.
Keywords: schizophrenia, tardive dyskinesia, 5-HT receptors, pharmacogenetics, gene polymorphisms
INTRODUCTION
The abnormal involuntary movement disorder tardive dyskinesia
(TD) is a common side effect of both first- and second-generation
antipsychotic drugs (Tenback and van Harten, 2011; Carbon
et al., 2017; Widschwendter and Hofer, 2019). The clinical picture
and course of TD is not unambiguously defined (Loonen et al.,
2019) and several other extrapyramidal movement reactions
occur simultaneously in patients treated with antipsychotic drugs
(Loonen et al., 2000, Loonen et al., 2001). These other drug-
induced movement disorders may also have a tardive course
and often accompany TD in fluctuating intensity which could
make it hard to correctly diagnose a case with dyskinesia in
epidemiological studies (Waln and Jankovic, 2013; D’Abreu et al.,
2018). Dyskinesia is known to occur spontaneously, particularly
in elderly persons (Woerner et al., 1991; Clark and Ram, 2007),
and also in drug-naïve persons with schizophrenia (Kane and
Smith, 1982; Pappa and Dazzan, 2009) as well as in their direct
relatives (McCreadie et al., 2003; Koning et al., 2010). This
spontaneously occurring dyskinesia may obscure the prevalence
of truly drug-induced movement disorders. Trying to identify
biomarkers which could predict vulnerability to develop TD
in individual patients using epidemiological data as starting
point is probably problematic in the yielding of fruitful results.
Pharmacogenetic information can better be applied to help
clarify the possible pharmacological mechanisms required in
the explanation of the pathogenesis of the movement disorder,
and/or the modification of the intensity of its symptoms
(Loonen et al., 2019).
TD is characterized by involuntary repetitive movements
which are usually abrupt and irregular in nature (Loonen and
van Praag, 2007). The movements may affect tongue, lips and jaw
as well as the forehead, eyelids (blinking), lower face and throat
(orofacial dyskinesia); the neck, trunk (rocking movements)
and upper and lower limbs may also show rapid repetitive
contractions (peripheral or limb-truncal dyskinesia). When
the diaphragm and intercostal muscles are affected, dyskinetic
movements result in making grumbling, snoring, groaning,
and/or sniffing noises (respiratory dyskinesia) (Van Harten and
Tenback, 2011). This last type is usually not considered in
epidemiological or treatment studies. In the earliest reports about
TD, this movement disorder was characterized by involuntary
orofacial movements (Loonen et al., 2019). This should be
considered to be “classic” TD (Waln and Jankovic, 2013). We
have observed that different gene variants are associated with
orofacial versus limb-truncal dyskinesia (Al Hadithy et al., 2009,
2010). We have also noticed that in levodopa-induced dyskinesia,
specific genetic associations exist with limb-truncal dyskinesia
(LID), but not with orofacial dyskinesia (Ivanova et al., 2012).
This may correspond with the observation that in Huntington’s
disease (HD) and LID, large muscle groups are often affected,
while in TD more subtle movements are present, most often
in the orofacial area. We could imagine that in TD the
dysregulation is primarily localized within another histological
striatal compartment than in HD and LID (Loonen et al., 2019).
TD most likely results from dysregulation within so-called
dorsal extrapyramidal cortico-striatal-thalamic-cortical (CSTC)
circuits (Loonen and Ivanova, 2013; Loonen et al., 2019). CSTC
circuits comprising the putamen as striatal entry station to the
basal ganglia regulate the intensity (amplitude and velocity)
of voluntary muscle contractions. The activity of these CSTC
circuits is in turn primarily regulated by ascending dopaminergic
nigrostriatal neurons. However, ascending serotonergic input
modulates the activity of CSTC circuits too (Loonen and
Ivanova, 2016; Loonen et al., 2019). 5-Hydroxytryptamine (5-HT,
serotonin)-containing fibers originating within brainstem upper
raphe nuclei have a widespread distribution within the midbrain
and forebrain (Loonen and Ivanova, 2016). They are heavily
connected with, for example, the substantia nigra pas compacta
(SNc), the dorsal striatum, and the frontal cerebral cortex, next
to many other structures. By affecting several components of
the CSTC circuits, they modulate their activity (Loonen and
Ivanova, 2016). Moreover, they affect the activity of CSTC circuits
indirectly via striatal interneurons and by modulating the stress
response (Loonen et al., 2019). Seven types of 5-HT receptors
(HTRs) can be distinguished, most of them having several
subtypes. All but one (HTR3) are g-protein coupled receptors
(GPCRs) (Hannon and Hoyer, 2008; Loonen and Ivanova, 2016).
For their role in TD and LID, HTR1A, HTR2A and HTR2C
have been most extensively studied (Meltzer, 2012; Huot et al.,
2013). HTR1A are inhibitory (receptors coupled to Gi/o) and
HTR2 are excitatory (receptors coupled to Gq/11) receptors.
A special characteristic of HTR2C and, to lesser extent, HTR2A,
is constitutive activity (Hannon and Hoyer, 2008). This offers
the possibility of certain atypical antipsychotic drugs having
inverse agonistic activity (Aloyo et al., 2009), which means that
they affect HTR2 in a direction opposite to 5-HT itself. This
complicates pharmacogenomic studies because it is not known
whether a genetic variant of the HTR2 gene affects the activity,
the expression, the inducibility or the constitutive activity of
the corresponding receptors. Therefore, an urgent need exists to
develop an in vivo or ex vivo test suitable to assess the activity
of receptor complexes corresponding to specific HTR2 variants
(Ivanova et al., 2018). Moreover, the use of drugs with inverse
agonistic activity, like atypical antipsychotics, could obscure the
possible consequences of HTR2 inactivity (Loonen et al., 2019).
The present study is aimed to investigate the possible role
of serotonin receptors in tardive dyskinesia and its subtypes in
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patients with schizophrenia by studying associations with specific
variants of HTR genes.
MATERIALS AND METHODS
Patients
The present study was carried out in accordance with The Code
of Ethics of the World Medical Association (Declaration of
Helsinki 1975, revised in Fortaleza, Brazil, 2013) for experiments
involving humans and after the study having been approved
(protocol N63/7.2014) by the Local Bioethics Committee of the
Mental Health Research Institute. Participants providing written
informed consent were recruited from three psychiatric hospitals
in Tomsk, Kemerovo and Chita oblasts in Siberia.
The study population was previously described (Boiko et al.,
2019; Levchenko et al., 2019). Patients were recruited who were,
or had been, using antipsychotic medication for more than 3
months and were on a stable dosage for at least 3 months
prior to entry. The inclusion criteria were a clinical diagnosis of
schizophrenia according to ICD-10 (F20) and an age of 18–75
years. Exclusion criteria were non-Caucasian physical appearance
(e.g., Mongoloid, Buryats or Khakassians); any relevant (e.g.,
unstable or acute) physical disorders, relevant pharmacological
withdrawal symptoms or organic brain disorders (e.g., epilepsy,
Parkinson’s disease). The severity of dystonia was assessed with
the Abnormal Involuntary Movement Scale (AIMS) (Loonen
et al., 2000; Loonen et al., 2001; Loonen and van Praag,
2007). The AIMS scores were converted into binary form
(presence or absence of tardive dyskinesia) according by Schooler
and Kane’s criteria (Schooler and Kane, 1982). Schooler–Kane
criteria require: (i) at least 3 months of cumulative exposure to
neuroleptics; (ii) the absence of other conditions that might cause
involuntary movements and (iii) at least moderate dyskinetic
movements in one body area (≥3 on AIMS) or mild dyskinetic
movements in two body areas (≥2 on AIMS). To compare
antipsychotic medications, all drug doses taken at the time of
investigation were converted into chlorpromazine equivalents
(CPZeq) (Andreasen et al., 2010). In order to exclude a
possible influence of drug-induced receptor inactivation on TD
scores, patients using 5-HT2A and/or 5-HT2C receptor blocking
antipsychotics (according to Loonen and Ivanova, 2016) were
excluded in sub-analysis.
DNA Analysis
Blood samples were obtained from each participant by
antecubital venepuncture. Blood with EDTA was stored in
several aliquots at −20◦C until DNA isolation. DNA from
leukocytes of whole peripheral blood was isolated according
with standard phenol-chloroform protocol. Genotyping was
performed without any knowledge of the patient’s clinical status.
Genotyping was carried out for 29 polymorphic variants of
HTR1A (rs6295, rs1364043, rs10042486, rs1800042, rs749099),
HTR1B (rs6298, rs6296, rs130058), HTR2A (rs6311, rs6313,
rs6314, rs7997012, rs1928040, rs9316233, rs2224721), HTR2C
(rs6318, rs5946189, rs569959, rs17326429, rs4911871, rs3813929,
rs1801412, rs12858300), HTR3A (rs1062613, rs33940208,
rs1176713), HTR3B (rs1176744) and HTR6 (rs1805054) on
the MassARRAY Analyzer 4 (Agena Bioscience). Rs1800042,
rs6314, rs12858300, rs33940208, and rs1176744 had a minor
allele frequency less than 5% or did not pass Hardy–Weinberg
equilibrium test (p < 0.05) and were excluded from analysis.
We used the set SEQUENOM Consumables iPLEX Gold
384. DNA sample preparation for SEQUENOM MassARRAY
Analyzer 4 includes several steps, including standard PCR
reaction, a shrimp alkaline phosphatase reaction to neutralize the
unincorporated dNTPs in the amplification products, the PCR
iPLEX Gold extension reaction, and then placing the samples on
a special chip (SpectroCHIP array) using Nanodispenser RS1000
prior to loading them into the analyser. DNA concentrations
were measured with a Thermo Scientific NanoDrop 8000
UV-Vis Spectrophotometer. Possibly relevant SNPs were
selected according to the literature data on associations with
schizophrenia and other mental disorders and program LD
TAG SNP Selection (TagSNP). More detailed information about
selected SNPs are presented in Supplementary Table S1.
Statistical Analysis
Statistical analysis was performed in the R statistical environment
using basic R functions, PredictABEL and the SNPassoc package
(Gonzalez et al., 2014). We conducted the statistical analysis in a
few steps. Firstly, we tested all polymorphic variants to deviation
from Hardy-Weinberg equilibrium with chi-square test, except
those variants which were located in X-chromosome (HTR2C
polymorphic variants). Polymorphic variants of HTR2C were
divided by sex and tested separately because of hemizygotic status
of X-chromosomal markers for men. In addition, polymorphic
variants with minor allele frequency less than 5% were excluded
from further testing. Secondly, we conducted association analysis
of genotypes and alleles with tardive dyskinesia and its orofacial
(AIMS item 1–4) and limb-truncal (AIMS items 5–7) subtypes
with chi-square test and Fischer’s exact test, where necessary.
Odds ratio and 95% confidence intervals (significance level was
0.05) were also tested. The third step was to assess variables
through binary logistic regression.
RESULTS
The total number of patients was 449 (226 females and 223
males). According to predefined criteria the total number of
patients with tardive dyskinesia was 121, thus the number
of patients without tardive dyskinesia was 328. The main
demographic and clinical parameters are presented in Table 1.
The mean age of patients with tardive dyskinesia (patients
with TD) was significantly higher than the age of patients
without tardive dyskinesia (patients without TD), and the
duration of schizophrenia was significantly longer in patients
with TD and higher doses of antipsychotics were used in
patients with TD. One hundred and ninety four patients received
typical antipsychotics (of which Haloperidol was the most often
used – 115 patients, Chlorpromazine – 44 patients, as well as
Chlorprothixene, Zuclopenthixol, Thioridazine, Periciazine). 172
patients received atypical antipsychotics (mainly Risperidone,
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Gender, n Male –152 (46.3%)
Female – 176
(53.7%)






37[31; 48] 48[37.5; 58] <0.001
Median age of onset
[Q1; Q3], years
24[20; 30] 25[20; 32] 0.974
Median duration of
illness [Q1; Q3], years
11[5; 18] 20[12;29.5] <0.001
Median CPZeq
[Q1; Q3], dose
396[200; 750] 500[286.2; 750] 0.021
[Q1; Q3] – [first quartile; third quartile].
Clozapine and Quetiapine and to a lesser extent Olanzapine,
Sertindole, Paliperidone, Amisulpride); 83 patients received
combined therapy.
The first step was to estimate a possible association between
the autosomal genotypes or alleles concerning HTR genes and the
presence or absence of total (Supplementary Table S2), orofacial
(Supplementary Table S3) or limb-truncal (Supplementary
Table S4) tardive dyskinesia. Almost all HTR variants showed
no association with TD or one of its subtypes. An exception was
formed by rs1928040 of the HTR2A gene. We found a significant
association of the T allele with a total diagnosis of tardive
dyskinesia (p = 0.02) and with orofacial TD (p = 0.02). The T allele
was also associated with limb-truncal TD, but this association did
not reach statistical significance (p = 0.07). The same was true for
the association of the genotypes with these first two forms of TD
(p = 0.061; p = 0.058, respectively) (Table 2). Excluding patients
who were treated with 5-HT2A antagonists according to Loonen
and Ivanova (2016) or periciazine (N = 185) hardly changed the
calculated ORs of possible associations, although significance was
lost due to the lower patient numbers and the resulting loss of
statistical power (data not shown).
The second step was to assess possible sex difference for
X-bound HTR2C variants (Supplementary Tables S5–S7). To
our surprise, we observed no association between any of the
HTR2C polymorphisms and total, orofacial or limb-truncal TD
in (hemizygous) males. In women, however, both genotypes and
alleles of HTR2C polymorphism rs1801412 were significantly
associated with total (p = 0.027, respectively, p = 0.03) and
orofacial TD (p = 0.008; p = 0.009). Limb-truncal TD was
not associated with this polymorphism for women (Table 3).
Excluding patients who used 5-HT2C antagonists changed the
measured ORs. In 141 female patients, the observed association
decreased for total and orofacial TD, but in 102 male patients it
increased for all three types of TD (Supplementary Tables S8,
S9). Due to the low patient number, a statistical trend (p = 0.08)
was reached only for orofacial TD in male patients.
The third step was to assess variables through binary
logistic regression (Table 4). We used the status of types
of tardive dyskinesia as the dependent variable, and “age,”
“gender,” “duration of disease” and significant polymorphic
variant rs1928040 as predictors. For orofacial TD Hosmer–
Lemeshow test, the result is chi-square = 6.627, p = 0.5773
(df = 8); AUC [95% CI] for orofacial TD model is 0.752 [0.698–
0.806]. For limb-truncal TD Hosmer-Lemeshow test, it is chi-
square = 5.86, p = 0.6629 (df = 8); AUC [95% CI] for limb-
truncal TD model is 0.700 [0.631–0.769]. For total diagnosis
of TD Hosmer-Lemeshow test, the result is chi-square = 8.674,
p = 0.3705 (df = 8); AUC [95% CI] for total diagnosis of TD model
is 0.746 [0.693–0.800].
The present study shows good values of AUC, which indicates
approximately good-fitted regression models for different types
of tardive dyskinesia in patients with schizophrenia. It revealed
that, compared with group of patients without TD, patients with
TD have significantly increased odds in variable “Duration of
disease” and significantly decreased in variables “Gender” and
“rs1928040” (Table 4).
DISCUSSION
The present paper describes the results of an association study
of in the end 24 polymorphic variants of HTR1A, HTR1B,
HTR2A, HTR2C, HTR3A, HTR3B, and HTR6 genes with TD
and two of its subtypes in 449 patients with schizophrenia.
As HTR2C is X-bound the possible association was studied
in male and female patients independently. We found a
significant association of the T allele of rs1928040 of the
HTR2A gene with total and orofacial TD. In addition, both
genotypes and alleles of HTR2C polymorphism rs1801412
was significantly associated with total and orofacial TD in
women, but not in men.
Rs1928040 is a C > T intron 2 variant of HTR2A gene
which is localized on chromosome 13. This variant has been
reported to be associated with the response to treatment with
selective serotonin uptake inhibitors (SSRIs) in patients with
major depressive disorders, but the results are inconsistent
(Kishi et al., 2010; Lucae et al., 2010; McMahon et al., 2006).
Rs1801412 is a T/G on position 114908141 of the HTR2C gene
on the X-chromosome. To our knowledge, an association with
central nervous system disorders has not been observed (Serretti
et al., 2009; Bakker et al., 2012); this includes antipsychotic-
induced movement disorders in a Dutch population of long-stay
psychiatric patients (Bakker et al., 2012).
An essential component of the pathogenesis of tardive
dyskinesia (Loonen and Ivanova, 2013) as well as levodopa-
induced dyskinesia (Ivanova and Loonen, 2016) is excitotoxic
damage to striatal medium spiny projection neurons (MSNs)
of the indirect extrapyramidal pathway (Loonen et al., 2019).
This slow damage could explain the late onset of the
movement disorder and the resulting dominance of dopamine
D1 carrying MSNs of the direct pathway, which is essential
for mediating dyskinesia (Westin et al., 2007; Darmopil
et al., 2009). We have hypothesized that second generation
antipsychotics (SGAs) can protect indirect pathway MSNs
against excitotoxicity by inverse agonism of HTR2A and
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TABLE 2 | Results of association analysis for genotypes and alleles of rs1928040 between groups of patients with different types of tardive dyskinesia and without
tardive dyskinesia.
SNP/TD type Genotypes/alleles Patients with TD, % Patients without TD, % OR χ2 p
Value 95% CI
rs1928040/orofacial TD TT 29 (26.9%) 50 (16.8%) 1.81 1.07–3.06 5.687 0.058
TC 47 (43.5%) 134 (45.1%) 0.94 0.60–1.46
CC 32 (29.6%) 113 (38.0%) 0.69 0.43–1.10
T 0.486 0.394 1.46 1.06–1.99 5.53 0.02
C 0.514 0.606 0.69 0.50–0.94
rs1928040/limbtruncal TD TT 18 (28.1%) 61 (17.9%) 1.80 0.97–3.31 3.795 0.150
TC 27 (42.2%) 154 (42.2%) 0.89 0.52–1.52
CC 19 (29.7%) 126 (37.0%) 0.72 0.40–1.29
T 0.492 0.405 1.43 0.98–2.08 3.39 0.07
C 0.508 0.595 0.70 0.48–1.02
rs1928040/total TD TT 31 (25.8%) 48 (16.8%) 1.72 1.03–2.87 5.601 0.061
TC 54 (45.0%) 127 (44.6%) 1.02 0.66–1.56
CC 35 (29.2%) 110 (38.6%) 0.66 0.41–1.04
T 0.483 0.391 1.46 1.07–1.97 5.89 0.02
C 0.517 0.609 0.69 0.51–0.93
Significancy (p < 0.05) indicated in bold.
TABLE 3 | Results of association analysis for genotypes and alleles of rs1801412 between groups of patients with different types of tardive dyskinesia and without
tardive dyskinesia after dividing by sex.
SNP/TD type Genotypes/alleles Patients with TD, % Patients without TD, % OR χ2 p-value
Value 95% CI
rs1801412/female/orofacial TD GG 0 (0.0%) 0 (0.0%) 4.32 0.08–220.72 7.138 0.008
GT 7 (16.7%) 9 (4.9%) 3.87 1.35–11.08
TT 35 (83.3%) 174 (95.1%) 0.26 0.09–0.74
G 0.083 0.025 3.61 1.30–9.98 6.88 0.009
T 0.917 0.975 0.28 0.10–0.77
rs1801412/female/limb-truncal TD GG 0 (0.0%) 0 (0.0%) 6.93 0.13–356.19 0.629 0.428
GT 3 (10.7%) 13 (6.6%) 1.70 0.45–6.38
TT 25 (89.3%) 184 (93.4%) 0.59 0.16–2.21
G 0.054 0.033 1.66 0.46–6.01 0.61 0.44
T 0.946 0.967 0.60 0.17–2.19
rs1801412/female/total TD GG 0 (0.0%) 0 (0.0%) 3.57 0.07–182.00 4.882 0.027
GT 7 (14.3%) 9 (5.1%) 3.09 1.09–8.79
TT 42 (85.7%) 167 (94.9%) 0.32 0.11–0.92
G 0.071 0.026 2.93 1.06–8.08 4.70 0.03
T 0.929 0.974 0.34 0.12–0.94
Significancy (p < 0.05) indicated in bold.
particularly HTR2C which these neurons carry (Loonen and
Ivanova, 2016; Loonen et al., 2019). Modulation of the
activity of HTR2A or HTR2C resulting from genetic variability
could then also result in differences in the incidence of
tardive dyskinesia during exposure to antipsychotic drugs. In
addition, fast spiking interneurons which inhibit the activity
of striatal dopaminergic terminals also express HTR2A or
HTR2C (Loonen and Ivanova, 2016; Loonen et al., 2019).
Inverse agonism by SGAs would increase the release of
dopamine, which could directly stimulate direct pathway MSNs
causing acute dyskinesia. Hence, present usage of HTR2A or
HTR2C antagonists could obscure a possible genetically induced
change in prevalence.
In our statistical analysis, both rs1928040 and rs1801412 were
linked more intensively to orofacial than to limb-truncal TD.
This corresponds to our previous observations that the genetic
background of these two types of TD may be different (Al
Hadithy et al., 2009, 2010). It has been suggested that the orofacial
variant corresponds to “classical” TD (Waln and Jankovic, 2013)
and is possibly related to a disfunction within another striatal
tissue compartment (i.e., striosomal) than HD and LID (i.e.,
matrix) (Loonen et al., 2019).
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TABLE 4 | Variables related with different types of tardive dyskinesia analyzed by binary logistic regression.
Type of tardive dyskinesia Category OR 95% CI lower bound 95% CI upper bound p-value
Orofacial TD rs1928040 0.6164 0.4366 0.8702 0.0060
Gender 0.2670 0.1514 0.4708 <0.0001
Age 1.0245 0.9966 1.0532 0.0856
Duration of disease 1.0615 1.0296 1.0945 0.0001
Limb-truncal TD rs1928040 0.6739 0.4585 0.9903 0.0445
Gender 0.4407 0.2385 0.8143 0.0089
Age 1.0278 0.9960 1.0606 0.0874
Duration of disease 1.0345 1.0010 1.0693 0.0437
Total TD rs1928040 0.6219 0.4453 0.8685 0.0053
Gender 0.3038 0.1767 0.5224 <0.0001
Age 1.0236 0.9967 1.0511 0.0856
Duration of disease 1.0619 1.0308 1.0940 0.0001
The usage of drugs which inactivate 5-HT receptors
may decrease the difference between different genotypes
corresponding to more or less activity of the corresponding
receptor product. As several SGAs have significant affinity to
HTR2A and somewhat less often to HTR2C, the usage of SGAs
may obscure possible associations. This was apparently not
true for HTR2A variants in our study. Excluding patients who
were using HTR2A antagonists hardly changed the observed
associations with TD (data not shown). This was also true
for rs1928040, although significance was lost, apparently due
to decreasing statistical power. This finding might also result
in a certain level of doubt about the functional consequences
of this rs1928040 variant. Excluding patients who were using
HTR2C antagonizing SGAs, however, changed the magnitude
of the associations. Due to the low number of the remaining
patients, no statistically significant differences were found,
but the size of the association between the G allele and
the presence of total and orofacial TD increased to a major
extent in the 102 studied (hemizygotic) men and decreased in
the 144 remaining women after excluding HTR2C antagonist
users. Our findings in men correspond to the prediction in
Loonen et al. (2019).
The most important limitation of our study is that our
finding cannot be applied to the identification of rs1928040
and rs1801412 as biomarkers because we assessed a possible
association with a total of 24 variants of 7 HTR genes. We wanted
to use our genotyping data to confirm or falsify our predefined
hypothesis about the possible role of HTR2 in mediating
“classical” TD symptoms. We did not find evidence supporting a
possible role for HTR2A, but the effect of excluding patients who
were using HTR2C antagonists indicates that HTR2C may have a
specific role in developing (especially orofacial) TD. The number
of male and female patients, who remain after excluding persons
using HTR2C antagonists, is small which limits the reliability of
this conclusion. Our findings should be verified in a prospective
study of (hemizygous) male patients who are only using classical
antipsychotics (or benzamides) devoid of HTR2 affinity. A third
limitation would be that the treatment history of our patients
cannot be adequately assessed. It should be emphasized that our
findings are at least partly related to acute effects on the severity of
the symptoms of TD (reflected by its prevalence). HTR2C could
also have a role in the pathogenesis (related to its incidence) of
this movement disorder, but this cannot be estimated.
CONCLUSION
In this study we obtained evidence for an association between
HTR2A polymorphism rs1928040 and HTR2C variant rs1801412
and particularly the orofacial form of tardive dyskinesia.
Excluding patients who were using 5-HT2 antagonists suggests
that HTR2C variety has functional consequences which may
indicate a role of this receptor in modulating the severity of TD.
However, this hypothesis needs verification in a larger group of
male patients who are not using HTR2 antagonists.
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